Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 6/20 | 0.62 |
| ▸ | DAGLA | Q9Y4D2 | 6/20 | 0.62 |
| ▸ | NCEH1 | Q6PIU2 | 1/20 | 0.62 |
| ▸ | FAAH | O00519 | 5/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4285196 | 0.80 | ATM (0.44) | CES1DAGLANCEH1SIGMAR1 | |
| SCHEMBL2162446 | 0.78 | FAAH (0.60) | CES1DAGLANCEH1FAAHLTA4H | |
| SCHEMBL2162583 | 0.77 | DAGLA (1.00) | CES1DAGLANCEH1FAAH | |
| SCHEMBL4293552 | 0.76 | DAGLA (0.72) | CES1DAGLANCEH1FAAH | |
| SCHEMBL4282566 | 0.75 | DAGLA (0.62) | CES1DAGLANCEH1 | |
| SCHEMBL4280672 | 0.73 | DAGLA (0.41) | CES1DAGLAFAAHSIGMAR1 | |
| SCHEMBL24665470 | 0.72 | S1PR1 (0.37) | CES1DAGLANCEH1 | |
| SCHEMBL4279402 | 0.71 | CES1 (0.64) | CES1DAGLANCEH1FAAH | |
| SCHEMBL12064926 | 0.70 | DAGLA (0.56) | CES1DAGLA | |
| SCHEMBL8094527 | 0.67 | SIGMAR1 (0.71) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009154785-A2 | C4-SUBSTITUTED ALPHA-KETO OXAZOLES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2009-12-23 | — | — | WO | claimed |
| WO-2009154785-A2 | C4-SUBSTITUTED ALPHA-KETO OXAZOLES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2009-12-23 | — | — | WO | disclosed |